Cereno Scientific has announced a regulatory milestone that materially shortens the development path for CS014, with Swedish authorities approving a focused FDA‑aligned PK study that replaces the need for further safety work and a Phase IIa trial.

Rather than signalling “another Phase I” this streamlined design is intended to accelerate CS014 directly toward Phase IIbin PH‑ILD by generating the comparative bioavailability data the FDA has already indicated will be sufficient for progression.

The study’s crossover PK approach in healthy volunteers is therefore a strategic shortcut, not a reset, enabling Cereno to leverage existing VPA data, strengthen the safety package efficiently, and keep the programme on track for Phase II initiation in early 2027.

More details on the news can be found on the Cereno Scientific website here.